Quantification of voriconazole in plasma by liquid chromatography-tandem mass spectrometry

被引:37
作者
Vogeser, M
Schiel, X
Spöhrer, U
机构
[1] Hosp Univ Munich, Inst Clin Chem, Munich, Germany
[2] Hosp Univ Munich, Dept Internal Med 3, Munich, Germany
[3] Hosp Univ Munich, Hosp Pharm, Munich, Germany
关键词
liquid chromatography-tandem mass spectrometry; solid phase extraction; therapeutic drug monitoring; voriconazole;
D O I
10.1515/CCLM.2005.124
中图分类号
R446 [实验室诊断]; R-33 [实验医学、医学实验];
学科分类号
1001 ;
摘要
A convenient liquid chromatography-tandem mass spectrometry method for the quantification of the triazole antifungal agent voriconazole in plasma samples is described. Fenbuconazole is used as an internal standard. After protein precipitation, automated solid-phase extraction is applied. Electrospray ionization in the positive mode is used and the following mass transitions are recorded: voriconazole, 350 -> 127; and fenbuconazol, 337 -> 125. The analytical run time is 4 min. The response was linear from 78 to 5000 mu g/L. The total coefficient of variation (n=16) was 12.6% for a low-concentration pool (143 mu g/L), 4.7% for a medium-concentration pool (419 mu g/L), and 5.0% for a high-concentration pool (4304 mu g/L). The method is proposed for future investigations that should be performed to test the hypothesis that therapeutic drug monitoring of voriconazole is clinically useful.
引用
收藏
页码:730 / 734
页数:5
相关论文
共 18 条
[1]   Adverse reactions to voriconazole [J].
Boyd, AE ;
Modi, S ;
Howard, SJ ;
Moore, CB ;
Keevil, BG ;
Denning, DW .
CLINICAL INFECTIOUS DISEASES, 2004, 39 (08) :1241-1244
[2]   Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis [J].
Denning, DW ;
Ribaud, P ;
Milpied, N ;
Caillot, D ;
Herbrecht, R ;
Thiel, E ;
Haas, A ;
Ruhnke, M ;
Lode, H .
CLINICAL INFECTIOUS DISEASES, 2002, 34 (05) :563-571
[3]   Tandem mass spectrometry in the clinical chemistry laboratory [J].
Dooley, KC .
CLINICAL BIOCHEMISTRY, 2003, 36 (06) :471-481
[4]   A rapid HPLC assay for voriconazole in human plasma [J].
Gage, R ;
Stopher, DA .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 1998, 17 (08) :1449-1453
[5]   Breakthrough invasive fungal infections in neutropenic patients after prophylaxis with itraconazole [J].
Glasmacher, A ;
Hahn, C ;
Leutner, C ;
Molitor, E ;
Wardelmann, E ;
Losem, C ;
Sauerbruch, T ;
Marklein, G ;
Schmidt-Wolf, IGH .
MYCOSES, 1999, 42 (7-8) :443-451
[6]   Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole [J].
Hyland, R ;
Jones, BC ;
Smith, DA .
DRUG METABOLISM AND DISPOSITION, 2003, 31 (05) :540-547
[7]   Voriconazole: A new triazole antifungal agent [J].
Johnson, LB ;
Kauffman, CA .
CLINICAL INFECTIOUS DISEASES, 2003, 36 (05) :630-637
[8]   Validation of an assay for voriconazole in serum samples using liquid chromatography-tandem mass spectrometry [J].
Keevil, BG ;
Newman, S ;
Lockhart, S ;
Howard, SJ ;
Moore, CB ;
Denning, DW .
THERAPEUTIC DRUG MONITORING, 2004, 26 (06) :650-657
[9]  
Ozawa Shogo, 2004, Drug Metab Pharmacokinet, V19, P83, DOI 10.2133/dmpk.19.83
[10]   Development and validation of a high-performance liquid chromatography assay for voriconazole [J].
Pennick, GJ ;
Clark, M ;
Sutton, DA ;
Rinaldi, MG .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2003, 47 (07) :2348-2350